Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...

An insight into one of NICE’s most long-standing collaborative relationships. For nearly 20 years, NICE has worked with the ...

There is a simple discount patient access scheme for trifluridine–tipiracil. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Trifluridine–tipiracil (Lonsurf, Servier Laboratories) plus bevacizumab is indicated for 'the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Venglustat for treating gangliosidoses in people 2 years and over [ID6358]. For information, ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) is available on the NHS. It is a possible treatment for metastatic colorectal cancer in adults who have had 2 lines of treatment (including ...